Android app Apple app link

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients

By Yahoo! Finance   |   1 week ago
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients

Candel Therapeutics announced positive survival data from a phase 2a trial of CAN-2409 in NSCLC patients inadequately responding to ICI treatment.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.